Skip to main content

Advertisement

Table 3 Cox regression models with total mortality as outcome for patients for patients aged ≥45 years with diagnoses of AF and diabetes mellitus ( n= 2,413) attending the 75 PHCCs between January 1st2001 and December 31st2007, stratified by age: 45–79 years (n = 1,704) and 80–104 years (n = 709)

From: Effects of prescribed antithrombotics and other cardiovascular pharmacotherapies on all-cause mortality in patients with diabetes and atrial fibrillation – a cohort study from Sweden using propensity score analyses

  Patients aged <80 years Patients aged ≥80 years All patients
  Full model Full model Full model
  HR (95% CI) HR (95% CI) HR (95% CI)
Antithrombotic drugs    
  Antiplatelets vs. no treatment 0.86 (0.43-1.72) 0.47 (0.26-0.87) 0.70 (0.45-1.09)
  Anticoagulants vs. no treatment 0.40 (0.17-0.91) 0.49 (0.24-1.00) 0.45 (0.26-0.77)
  Anticoagulants vs. antiplatelets 0.44 (0.25-0.78) 1.02 (0.60-1.73) 0.62 (0.42-0.92)
Digitalis 0.81 (0.54-1.23) 0.90 (0.60-1.35) 0.83 (0.62-1.11)
Loop diuretics 2.42 (1.36-4.33) 1.02 (0.60-1.73) 1.55 (1.06-2.28)
Thiazides 0.98 (0.59-1.63) 0.89 (0.55-1.44) 0.93 (0.66-1.32)
Aldosterone antagonists 1.20 (0.76-1.88) 1.22 (0.79-1.88) 1.29 (0.94-1.77)
Beta blockers 0.62 (0.40-0.97) 0.73 (0.49-1.10) 0.67 (0.49-0.90)
RAS-blocking agents 1.08 (0.65-1.78) 1.23 (0.79-1.93) 1.16 (0.83-1.62)
Calcium receptor-blocking agents 1.06 (0.69-1.63) 1.20 (0.77-1.87) 1.10 (0.81-1.49)
Statins 0.45 (0.29-0.71) 0.77 (0.47-1.26) 0.56 (0.40-0.78)
  1. Full model is adjusted for a propensity score comprising sex, age group, co-morbidities, educational level, marital status and for all pharmacotherapies. HRs and 95% CIs are shown. Statistically significant HRs are highlighted in bold.